PRESS RELEASES
CERUS Resources at Business.com
(BioPortfolio.com)
Hoover’s Archived News Items (via Northern Light
Disclaimer: Opinions posted on Free Republic are those of the individual posters and do not necessarily represent the opinion of Free Republic or its management. All materials posted herein are protected by copyright law and the exemption for fair use of copyrighted works.
Donated blood can be scrubbed free of a range of diseases, such as HIV, by adding a chemical and bathing the blood in a beam of light, a company reported yesterday. The technique, developed by a Californian firm, Cerus, is undergoing clinical trials and could be approved for use in America next year. One chemical, psoralen, is designed to penetrate cells, viruses, bacteria and other pathogens where it seeks out RNA and DNA. When bathed in ultraviolet light for three minutes, the chemical forms a crosslink across the double helix of genetic material, disabling it.
PRESS RELEASES
CERUS Resources at Business.com
(BioPortfolio.com)
Hoover’s Archived News Items (via Northern Light
Links only to the articles includes (with links) below:
RECENT DEVELOPMENTS:
FINANCIAL:
- JUNE 6, 2001: ON24 Audio Investor Alert: Expert: Cerus Process for Blood Testing Will Skip Over Prions
- JUNE 5, 2001: ADM Tronics' Researchers Applaud USA Today Story on Cerus Blood Treatment (also by (Market News Publishing via COMTEX)
- JUNE 4, 2001: New Procedure May Help Blood Supply (June 4, 2001 8:20pm)
- MARCH 19, 2001: CERUS Gets Big Pentagon Boost(by Leslie Mladinich)
- MARCH 7, 2001: Cerus targets military blood supply
- JANUARY, 2001: Cerus partners with Kirin Brewery
- FEBRUARY, 1997: CERUS goes public in February, 1997 (raising 24 million at $12/share)
- DECEMBER, 1998: Cerus to Receive Funding from the Consortium for Plasma Science to Develop New Approach for Inactivating Pathogens in Human Blood Plasma for Fractionation
The Consortium for Plasma Science seeks to provide R&D funding worldwide for a universal approach to eradicate pathogens from human plasma without destroying the functionality of the plasma proteins. The Consortium is co- funded by four plasma fractionation companies, which share safety as a common goal: Alpha Therapeutics Corporation, a unit of the Japanese pan-national Yoshitomi; Bayer Corporation; Baxter Healthcare Corporation; and Centeon, a joint venture of Hoechst and Rhone-Poulenc. The Consortium, which is a separate entity from its member companies hopes to accelerate the emergence of new technologies.
- JANUARY, 1999: Robust Growth Is in Cerus' Blood (Businessweek; BY GENE G. MARCIAL)
- AUGUST, 2000: CERUS Raises 60 Million in Private Placement
- MAY, 2001: On May 17 2001, CERUS announced private placements totalling $78 Million
- Cerus raises $78 million in new stock issue (East Bay Times)
Trials have consumed nearly seven years, but in that time, Cerus has signed some key partnerships.This year, Cerus signed a $3.5 million deal with the Pentagon to develop blood testing tests for exotic diseases found in primarily military blood supply, and it stands to receive $12 million from Kirin Brewery in Japan. The company, which has a stem cell division, will license Cerus's Helinx technology, the pathogen deactivation technology found in all of Cerus's systems.
June 6, 2001 5:52pm
Business Editors & Analysts --(BUSINESS WIRE)--ON24 Contributor Dr. Jordan Shlain discusses Cerus' Helinx process for blood testing.
For the complete streaming audio story users should access http://www.on24.com/index.html?id=59189&type=av&ref=bizwire
Ticker: (NASDAQ:CERS)
Company: Cerus Corporation
NORTHVALE, N.J.--(BUSINESS WIRE)--June 5, 2001--Researchers at ADM Tronics (OTC BB:ADMT) applaud USA Today for its June 4 cover story A Ray of Light for Blood Supply, about a process being developed by Cerus of Concord, CA involving treatment of donated blood with ultraviolet light.The ADMT researchers are pleased with the story due to awareness this could bring to research being done at ADMT for, what they believe is a more far-reaching technology based on similar science. ADMT subsidiary, Immuno-Therapy Corporation (ITC), is developing the ITC Hemo-Irradiator, a process where ultraviolet light, similar to as described in the USA Today story, is used to inactivate pathogens, not in donated blood as being done by Cerus, but directly in a patient's blood to help fight various diseases.
The process involves drawing a small sample of blood, exposing it to ultraviolet light to inactivate pathogens, then returning the blood to the patient as an auto-immune injection - all in a closed system. Initial tests have been promising and ITC is preparing for wider clinical evaluations for submission to the FDA. We are glad that USA Today is helping to bring awareness of the significant medical potential of ultraviolet light, stated Andre' Di Mino, COO of ADMT, This helps us in our efforts at bringing our ITC Technology to fruition.
ITC technology is derived from a treatment in use decades ago for treating blood-borne diseases. The Knott Technique of Ultraviolet Blood Irradiation with the Knott Device was widely used from the 1940s to 1960s until virtually supplanted by the proliferation of antibiotics. Consequently the device was no longer manufactured although some physicians continued the treatment. Due to the surge in antibiotic-resistant diseases several years ago, interest in alternative treatments accelerated. The ITC Hemo Irradiator, under development for 5 years, is aimed at bringing the Knott device to today's standards.
ADM Tronics is a technology-based developer and manufacturer of diversified products, categorized into three market segments - therapeutic, non-invasive electronic medical devices, environmentally safe chemical products and innovative dermatological products.
Statements in this release that are not historical facts are forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to risks and uncertainties, detailed in the Company's filings with the SEC, that could cause actual results to differ materially from estimated results.
SAN FRANCISCO (AP) A key part of the nation's blood supply could be made safe from viruses, bacteria and parasites with the use of a chemical activated by ultraviolet light, a biotech company said Monday.Cerus Corp. said it has performed hundreds of successful tests on blood products using a process it calls Helinx, which attacks strands of genetic material at the center of all living things and prevents DNA and RNA from replicating.
The process doesn't work with red blood cells, because they are too opaque for ultraviolet light to penetrate. But it renders killer viruses and bacteria harmless in translucent platelets and plasma, Cerus said.
Dr. Bernadine Healy, national director for the American Red Cross, said the procedure could add significant protection to the blood supply.
Obviously, we're very excited about this, she said. From the perspective of the Red Cross, we see it as a way to screen pathogens, viruses or parasites that we don't test for or don't know about.
The Red Cross already screens for 13 viruses and pathogens in donated blood, including hepatitis, syphilis and HIV, Healy said.What sets Helinx apart is that it attacks any viruses, known and unknown, Cerus said. It prevents replication in any cell containing genetic material; blood cells have no RNA and don't reproduce. Using this process we can protect the blood supply from new disease-causing organisms without having to know specifically what they are, said CEO Stephen Isaacs. So it's kind of like an umbrella for the blood supply. Isaacs and University of California, Berkeley, professor John Hearst, both chemists, worked with Larry Corash, a hematologist, for about a decade to develop the procedure.
A light-activated photochemical is added to plasma and platelets that have been separated from red blood cells. The chemical mixes with any genetic material, and when exposed to ultraviolet light, forms a permanent bond with DNA and RNA, preventing the strands from replicating. Viruses and bacteria that can't reproduce do little harm
The side effects of the chemical called psoralen are not yet clearly known, Healy said, and the process has yet to receive Food and Drug Administration approval. She estimated the cost at $70 to $80 a unit of blood product: But if that's the price we pay for a safer unit of blood, I believe it is our obligation to do that.
White blood cells, where viruses and bacteria sometimes lurk, are also inactivated by the procedure. The Red Cross currently uses a process called leukoreduction to rid blood products of white blood cells. This alone costs $30 a unit, Healy said. To make platelets and plasma pathogen-free is a big step, but it's important to note that the ultraviolet-light procedure cannot be used on red blood cells, Healy said. And red blood cells account for the greatest number of transfusions in the United States about 13 million a year, said Scott Murphy, senior medical scientist with the Red Cross' Pennsylvania-New Jersey region. Platelets account for only about 2 million transfusions a year.
Isaacs said studies show treated blood products work as well as non-treated. Clinical trials on platelets are complete and trials for plasma are nearly complete, he said. Isaacs predicted treated platelet products will be on the European market early next year and the U.S. market at the end of next year. Plasma should be on the market by 2003.
Healy noted that the method will not neutralize the human form of mad cow disease, which contains pure proteins without DNA or RNA. Even if new methods are approved, the Red Cross will continue to use many other safeguards to prevent infected blood from entering the supply, she said. "There's no one magic bullet. We'll still be testing our blood for major pathogens."
Cerus Corp. is embarking on a $3.5 million mission for the Pentagon that will put the Concord firm face to face with such rare diseases as Congo Crimean hemorrahgic fever and lieshmania.Cerus Vice President John Hearst sees the special military assignment as a great business opportunity because throughout the investigation of inactivating new pathogens with new technology, the company gets to keep any new discoveries and inventions that arise from the research.
Any technology Cerus would create under the agreement has the potential to reach the 70 million U.S. units of blood that are collected each year because donations from armed forces are mixed with those from civilians.
"There isn't such a thing as an isolated blood supply any longer," said Dr. Laurence Corash, Cerus' chief medical officer.
The key objective of the Department of Defense contract is to detect diseases of particular interest to the U.S. Army that make it into the blood supply from armed forces needing and donating blood in far-off areas where the process of screening and storing blood isn't as advanced as it is in the United States.
For example, South Africa has a modern blood banking system, but some diseases still go undetected. If the bank thinks a donor's blood could contain malaria, depending on what region they are from, stickers are plastered to bags reading "Could contain malaria."
"That is the best they can do," said Corash. "There is no test for malaria."
Corash explained that the military agreement allows the company to demonstrate technology that kills maladies like malaria.
"We can share that with the people of South Africa, and use the technology to support scientific claims. We can take it to the regulatory authorities in South Africa and show that we can inactivate malaria," he said.
The technology Cerus will seek to develop for the Pentagon will be based on three different blood pathogen deactiviating systems. The company is testing those systems in Phase III clinical trials in the United States and Europe. The systems target platelets, plasma or red blood cells and stop the reproduction of viruses, bacteria and destructive cells. Most of the military work will focus on red blood cells.
The trials have consumed nearly seven years. Cerus is closer to winning marketing approval in Europe, where trials are going on in four countries.
Cerus, unknown to the general public, still lacks a marketable product. Nevertheless, the company is widely recognized in the specialized blood safety industry and the military contract is one more affirmation.
The military has had a blood research program since World War II. In 1999, Cerus spoke before Congress on the topic. Last year, Congress gave more money for research. U.S. Rep. George Miller, D-Martinez, strongly supported putting more money toward blood safety research. Cerus applied for the cooperative agreement, but won out among other companies.
Hearst says the vast amount of research Cerus will be doing should lead to more work for the company. "We have to work on a pipeline after our three major products," he said.
Cerus of Concord was awarded a contract by the U.S. Department of Defense to develop and use technology for improving the safety of the blood supply in the armed forces. The $3.5 million agreement, initiated by the Army Medical Research Acquisition Activity, was supported by legislators Rep. George Miller, D-Martinez, and Nancy Pelosi, D-San Francisco.Cerus will research ways to improve the storage and shelf life of blood which may be used for medical transfusion support in combat zones and will be able to keep commercial rights for the discoveries involved in the project. Cerus is developing medical systems and therapeutics based on what the company calls its Helinx technology, which targets DNA and RNA and prevents the replication of viruses and other pathogens.
>
Concord's Cerus and the pharmaceutical division of Kirin Brewery in Japan will collaborate on stem cell transplantation technologies to fight graft-verus-host disease, a common condition associated with the somewhat controversial transplant method.The products in development are being designed to improve the outcome of stem cell transplant therapy by treating white blood cells, or leukocytes. Cerus, which is trying to make itself known by developing blood safety technology, will initially license its Helinx technology for $1 million to Kirin, and then receive $11 million in future development milestone payments.
Cerus and Kirin will try to treat hematologic malignancies such as leukemia and lymphoma. Cerus and Kirin are jointly developing the technologies.
On August 29, 2000, CERUS "raised $60 million in cash in a private placement of 1.2 million newly issued shares of its common stock to an undisclosed institutional investor at a price of $50 a share".
Concord, CA and Charlotte, NC, December 15, 1998 -- Cerus Corporation (Nasdaq: CERS) and the Consortium for Plasma Science, LLC jointly announced today an agreement to develop and commercialize systems to advance the safety of plasma-based products through the inactivation of pathogens and other infectious agents in source plasma prior to processing. Cerus is developing methods to inactivate viral pathogens and other infectious agents in human blood products including source plasma; the starting material employed in manufacture of clinically useful plasma-based therapeutics.The agreement includes an initial commitment to fund development of Cerus' proprietary S-59 technology for use with source plasma. Cerus initially developed its S-59 technology for platelets and plasma intended for transfusion. The agreement contemplates funding by the Consortium through the regulatory approval phase, with future commitments to be determined by the Consortium annually. The agreement provides for Cerus to pay the Consortium a royalty on potential product sales.
"Blood safety in the developed world is state of the art, and the risk for infection by transmission during transfusion has never been lower," said Dr. Frederick Dombrose, Executive Director of the Consortium. "However, vigilance and continued improvement remain a goal because of general concern for the possible transmission of unknown or undetectable pathogens. Maintaining the safety of transfused human blood-derived products depends heavily on the dual safeguards of donor screening and pathogen testing, in combination with [GAG ALERT:] the plasma fractionation industry's commitment to quality assurance," Dombrose added.
"The Consortium is a progressive organization in its active pursuit of new technologies to enhance the safety of the blood supply. This agreement will help open the door for Cerus into the significant plasma fractionation side of the blood products industry,," said Cerus president and Chief Executive Officer Stephen Isaacs. "Strategically, the treatment of source plasma is a perfect fit for our technology. We believe we can leverage our expertise, gained from our work in developing the S-59 technology for the treatment of blood products for transfusion, to enhance the safety of plasma-derived products."
Cerus Corporation is developing medical applications for its proprietary nucleic acid-targeting technologies including its proprietary light-activated compound, S-59, and its proprietary pH-activated anchor-linker- effector (ALE) compound, S-303. The company is developing pathogen inactivation systems for blood components for transfusion (platelets, plasma and red blood cells) using these proprietary technologies. Programs for each of the three components are currently in clinical trials.
Single donations of whole blood can be processed into three primary components: red blood cells, which contain oxygen-carrying hemoglobin; platelets, which are specialized cells that can support clotting; and plasma, the liquid portion containing therapeutic proteins. Following required testing and blood typing, blood components can be transfusions for important clinical therapies. Human plasma may also be pooled from numerous donors and processed through plasma fractionation into several specialized components such as clotting factors, immunoglobulins, albumin and fibrinogen.
The Consortium for Plasma Science seeks to provide R&D funding worldwide for a universal approach to eradicate pathogens from human plasma without destroying the functionality of the plasma proteins. The Consortium is co- funded by four plasma fractionation companies, which share safety as a common goal: Alpha Therapeutics Corporation, a unit of the Japanese pan-national Yoshitomi; Bayer Corporation; Baxter Healthcare Corporation; and Centeon, a joint venture of Hoechst and Rhone-Poulenc. The Consortium, which is a separate entity from its member companies hopes to accelerate the emergence of new technologies.
This news release contains forward-looking statements that involve risks and uncertainties. Actual results could differ materially from the above forward-looking statements as a result of certain factors, including the uncertainty of the timing and results of any trials, regulation by the FDA, the uncertainty of replication of animal data in humans, the uncertainty of market acceptance of any products, competitive conditions, the uncertainty of future financing and other factors discussed in Cerus Corporation's 1997 Annual Report on Form 10-K.
No, Cerus (CERS) (CERS) isn't an Internet stock. But it has nearly doubled in just three months--from 11 1/4 a share on Oct. 9 to 21 on Jan. 12. On Jan. 13, Morgan Stanley Dean Witter put the stock on its ''strong buy'' list, pushing the stock to 24 9/16. And it looks poised to head even higher, argue some pros. Certain big investors have discovered Cerus, which addresses a tremendous global problem: blood contamination. Cerus is a pioneer in developing viral ''inactivation'' systems that act to decontaminate blood components and to improve the safety of transfusions.Baxter International (BAX), a global leader in technologies associated with the circulatory system, has acquired a 17% stake in Cerus and has signed a strategic pact to develop and market its plasma-inactivation processes. And the Consortium of Plasma Science, made up of key players in the industry--including Bayer, Alpha Therapeutic, and Baxter--has also agreed to fund Cerus' development of methods to inactivate pathogens in plasma.
The consortium will provide $2 million in the first year and then fund development through regulatory approval. ''The clinical data have been compelling,'' says Katherine Martinelli, an analyst at SG Cowen Securities in Boston. The Food & Drug Administration has given approval for Phase III clinical trials on the inactivation system for platelets, which Martinelli expects will get under way in the first quarter. Similar tests are being done in Europe.
With some 60 million transfusions worldwide every year, the potential for Cerus' technology is enormous, says Martinelli. ''We look for Cerus to receive approval overseas for its platelet system in late 2000, and in the U.S. by 2001,'' she adds. So revenues should ramp up in 2001, and Cerus should be in the black by 2002, she says.
Analyst Kevin Tang of BT Alex. Brown notes that the technology has been shown in a number of clinical studies to be effective at inactivating pathogens without adversely affecting plasma or platelets. He estimates the market for Cerus' systems at about $2 billion. Tang figures Cerus will earn $2.41 a share in 2002 and $6.56 in 2003, based on revenues of $112 million and $238 million, respectively.
Cerus raises $60M in private placement
By Jeff Shuttleworth, LocalBusiness.com
Aug 29, 2000 03:34 PM ETCONCORD, Calif., Aug. 29 (LocalBusiness.com) -- Cerus Corp., a company focusing on blood purification know-how, raised $60 million in cash in a private placement of 1.2 million newly issued shares of its common stock to an undisclosed institutional investor at a price of $50 a share.
Concord, Calif.-based Cerus (Nasdaq: CERS) said the financing gives it cash and investments totaling $106 million. This will keep it in good financial shape until it brings products to market in the next three years.
Cerus said it will use the net proceeds from the private placement to fund research and development, including clinical trials, as well as for operating expenses and capital expenditures.
Greg Schafer, the company's chief financial officer and vice president of finance, declined to name the institutional investor, but said it's "a well-known and well-respected Midwestern investor." The firm's name will be disclosed in the company's next regulatory filing, he said.
The investor doesn't want its name disclosed now because of concerns the transaction "would be mistaken as an acquisition," Schafer said.
The Company has entered into two development and commercialization agreements with Baxter Healthcare Corporation to develop, manufacture and market these pathogen inactivation systems.Or was Archer Daniels Midland’s ADMTronics the “Midwesterner”? (See related stories above in “Developments”)
"This financing significantly strengthens our balance sheet and provides additional resources to fund our R&D," Cerus president and CEO Stephen Isaacs said in a statement."It's a critical time for Cerus" because the company is preparing for regulatory approval in Europe for its pathogen inactivation system for platelets, which are cellular elements in the blood essential for clotting, Isaacs said.
Cerus is in U.S. Phase III trials for its platelet treatment as well as for its system to inactivate viruses, bacteria and other pathogens in fresh frozen plasma. Additionally, Cerus is in Phase I trials for its system to inactivate viruses, bacteria and other pathogens in red blood cells intended for transfusion.
The company's goal is to purify the more than 100,000 units of blood and blood products that are transfused each day in North America, Western Europe and Japan to treat a wide variety of medical conditions. Many of the transfusions carry potentially harmful viruses and bacteria, such as HIV, hepatitis and herpes.
Isaacs estimates the market for the decontamination systems Cerus is focusing on is about $2 billion annually.
Analyst Katherine Martinelli of Merrill Lynch rates Cerus as "near-term accumulate and long-term buy" and estimates it will become profitable by 2003. Martinelli estimates that Cerus' platelet system will be on the market in Europe by the end of 2001 and in the United States by the end of 2002.
Schafer said the company's plasma product also is expected to be on the market by the end of 2002 and the red blood cell system is expected to be on the market in 2003 or 2004.
For the second quarter ended June 30, Cerus had $541,000 in revenue, up from $434,000 in revenue for the second quarter of 1999. Cerus had a net loss of $8.5 million in the second quarter, compared with a net loss of $5.5 million for the same quarter last year.
In mid-afternoon trading Tuesday, shares of Cerus rose 31 cents, or 0.57 percent, to $55.31. Its 52-week range is a high of $78.50 and a low of $20.38.
CONCORD, Calif.--(BUSINESS WIRE)--May 17, 2001--Cerus Corporation (Nasdaq:CERS) today announced that it has completed the sale of 1,000,000 newly issued shares of common stock to an institutional investor at a purchase price of $52.00 per share. Morgan Stanley served as the placement agent for this transaction.In a separate [$26 MILLION] transaction, Baxter International Inc. and Subsidiaries Pension Trust has purchased 500,000 newly issued shares of Cerus common stock at a purchase price of $52.00 per share. Cerus expects to use the net proceeds from these financings to support research and development, including late-stage clinical trials, and for pre-commercialization activities, general and administrative expenses, capital expenditures and working capital. The company has agreed to file with the SEC resale registration statements relating to the privately placed shares.
We are pleased to strengthen our balance sheet with this additional financing, said Stephen T. Isaacs, president and chief executive officer. The transaction is timely as we progress further with late-stage product development and prepare for potential commercialization of the INTERCEPT Blood Systems. In addition, the proceeds will help fund development of our pipeline focused on innovative therapeutics.
The INTERCEPT Blood Systems are designed to inactivate viruses, bacteria, other pathogens and white blood cells in donated blood components intended for transfusion. Cerus is jointly developing the systems with Baxter Healthcare Corporation. In collaboration with Baxter Healthcare Corporation, Cerus has submitted a CE Mark application for the INTERCEPT Platelet System for marketing approval of the product in Europe and has completed a Phase III clinical trial in the United States. In addition, the INTERCEPT Plasma System also is in Phase III clinical trials and the companies are currently preparing for Phase III trials of the INTERCEPT Red Blood Cell System.
ABOUT CERUS Cerus Corporation is building on its leading position in the biopharmaceutical industry by developing medical systems and therapeutics to provide safer and more effective options to patients. The company is developing products based on its proprietary Helinx? technology for controlling biological replication. Cerus' most advanced programs are focused on systems to enhance the safety of the world's blood supply. These INTERCEPT Blood Systems, based on the company's Helinx technology, are designed to inactivate viruses, bacteria, other pathogens and white blood cells. The Concord, California-based company also is pursuing therapeutic applications of Helinx technology to treat and prevent serious diseases.
Statements in this news release regarding financing plans, product development and product potential are forward-looking statements that involve risks and uncertainties. Actual results could differ materially from the above forward-looking statements as a result of certain factors, including the risks and uncertainty of the timing and results of clinical trials and other development activities, actions by regulatory authorities at any stage of the development process, additional financing activities, market acceptance of any products, competitive conditions, corporate partnerships and other factors discussed in the company's most recent Report on Form 10-Q.
Institutional investors are taking stock of Cerus, as the Concord blood safety biotech raised $78 million by selling 1.5 million newly issued shares of common stock.Cerus said it will use the money for research and development, including late-stage clinical trials, and to pay for expenses before its testing systems reach market. Cerus's Intercept Blood System is designed to inactivate viruses, bacteria, and other pathogens and white blood cells in donated blood in three forms: platelets, plasma and red blood cells.
Cerus is farther along with in getting a product to market in Europe than United States, although the tests are in clinical trials both here and abroad. Trials have consumed nearly seven years, but in that time, Cerus has signed some key partnerships.
This year, Cerus signed a $3.5 million deal with the Pentagon to develop blood testing tests for exotic diseases found in primarily military blood supply, and it stands to receive $12 million from Kirin Brewery in Japan. The company, which has a stem cell division, will license Cerus's Helinx technology, the pathogen deactivation technology found in all of Cerus's systems.
|
BLOOD TRAIL: THE BLOOD BROKERS PART 1 -- HOW BLOOD,
THE 'GIFT OF LIFE,' BECAME A BILLION-DOLLAR BUSINESS Source: PHILADELPHIA INQUIRER Published: September 24, 1989 Author: Gilbert M. Gaul Posted on 07/12/1999 19:45:35 PDT by Wallaby (348)
BLOOD TRAIL: THE BLOOD BROKERS PART 2 - THE LOOSE
WAY THE FDA REGULATES BLOOD INDUSTRY Source: PHILADELPHIA INQUIRER Published: September 25, 1989 Author: Gilbert M. Gaul Posted on 07/12/1999 20:45:42 PDT by Wallaby (347)
BLOOD TRAIL: THE BLOOD BROKERS PART 3 -- FEAR OF AIDS
SPURS CHANGE Source: PHILADELPHIA INQUIRER Published: TUESDAY September 26, 1989 Author: Gilbert M. Gaul Posted on 07/12/1999 21:00:40 PDT by Wallaby (346)
BLOOD TRAIL: THE BLOOD BROKERS PART 4 -- RED CROSS:
FROM DISASTER RELIEF TO BLOOD Source: PHILADELPHIA INQUIRER Published: WEDNESDAY September 27, 1989 Author: Gilbert M. Gaul Posted on 07/12/1999 21:44:11 PDT by Wallaby (345)
BLOOD TRAIL: BLOOD BROKERS, PART 5, LAST IN SERIES --
AMERICA: THE OPEC OF THE GLOBAL PLASMA Source: PHILADELPHIA INQUIRER Published: September 28, 1989 Author: Gilbert M. Gaul Posted on 07/12/1999 22:14:30 PDT by Wallaby (344)
Red Cross Going to Refuse Money Raised by Hillary Protest Banner Auction
LIDDY DOLE'S RED CROSS RUNS AMOK
[
Reply |
Private Reply | Top | Last ]
The Consortium for Plasma Science seeks to provide R&D funding worldwide for a universal approach to eradicate pathogens from human plasma without destroying the functionality of the plasma proteins. The Consortium is co- funded by four plasma fractionation companies, which share safety as a common goal: Alpha Therapeutics Corporation, a unit of the Japanese pan-national Yoshitomi; Bayer Corporation; Baxter Healthcare Corporation; and Centeon, a joint venture of Hoechst and Rhone-Poulenc. The Consortium, which is a separate entity from its member companies hopes to accelerate the emergence of new technologies.
I got that far and had to quit Googling (as well as bag my plans for lunch ... I've no appetite all of a sudden).
For further Googling around later ...
I can't format to save my life lately.
fix?
[
Reply |
Private Reply | To 3 | Top | Last ]
Next step treatment for blood bourne diseases via transfusion?
A bump for you and the blood trail.
Next step treatment for blood bourne diseases via transfusion?
More like consolidation (in partnership with the government and the private corporations who spread tainted blood worldwide in the first place) of all public and anonymous "private investor" eggs in one Basket.
They made insane amounts of money spreading the disease and now stand to recoup insane amounts of money protecting the public from the next "unknown" ...
Welp ... Hizzoner says: GO HOME.
I'd probably be better off with a pirogue than a parasol, looking at the skies.
I'd probably be better off with a pirogue than a parasol, looking at the skies.
That's for sure. Hope you and Mr. B have a great weekend.
hmmm I didn't know malaria could be passed through blood transfusions. I always thought my ex-husband, who died from malaria, got bit by a mosquito in Africa. I wonder if instead he got it through a blood transfusion. If I am remembering correctly, he got blood when he was bleeding from an ulcer. I don't remember the time frame though.
I hope this is for real. Remember a few years ago when some scientists claimed that blood could be heated to a sufficent amount and kill the HIVirus and then be returned to the host?
Given the cluster of government and "Consortium" money surrounding CERUS, looks promising. =)
Just think some of the parmacutical companies backing this effort also supported medical testing at concentration camps in Germany and Camp 731 war crimes in China.
a bump!
I'll admit that it was the Blood Trail (more than any inhumanity to man I've ever read about or seen) that convinced me of the absolute enormity of some men's hearts.
You like to think, sometimes, that it's circumstances beyond their control what makes men perpetrate evil. Now I now better ... they purpose it.
IF the light treatment works it will be a Godsend.
Disclaimer: Opinions posted on Free Republic are those of the individual posters and do not necessarily represent the opinion of Free Republic or its management. All materials posted herein are protected by copyright law and the exemption for fair use of copyrighted works.
[
Top
|
Latest Posts
|
Latest Articles
|
Self Search
|
Add Bookmark
|
Post
|
Abuse
|
Help!
]
FreeRepublic , LLC, PO BOX 9771, FRESNO, CA 93794 Forum Version 2.0a Copyright © 1999 Free Republic, LLC |